Document is current
Any future updates will be listed below
-
Authors
Morin, Gabriel https://orcid.org/0000-0002-8423-6701
Fraissenon, Antoine https://orcid.org/0000-0003-4414-1246
Chopinet, Caroline
Balducci, Estelle
Kaltenbach, Sophie
Villarese, Patrick
Asnafi, Vahid
Guibaud, Laurent
Canaud, Guillaume https://orcid.org/0000-0002-9901-8635
- License Information
-
More Information
Article History
Received: 22 January 2025
Revised: 28 April 2025
Accepted: 23 May 2025
First Online: 6 June 2025
Competing interests
: A patent application (“BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum” #WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Cité, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES syndrome). GC is the inventor. This patent is licensed to Novartis. GC receives or has received consulting fees from Novartis, Fresenius Medical Care, Vaderis, Alkermes, IPSEN, BridgeBio, Vertex and Medetia. The other authors declare no other competing interests.
: Treatment authorization was obtained from the French Regulatory Agency - Agence nationale de sécurité du médicament et des produits de santé (ANSM - reference numbers: 1013795, 1098458 and 1098458). Signed and informed consent was obtained from all subjects. Written informed consent for publication of images was obtained for all patients.
